Share This Page
Drug Price Trends for NDC 00168-0264
✉ Email this page to a colleague
Average Pharmacy Cost for 00168-0264
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00168-0264
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ALCLOMETASONE DIPROPIONATE 0.05% OINT,TOP | Sandoz, Inc. | 00168-0264-15 | 15GM | 8.92 | 0.59467 | 2023-08-15 - 2028-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00168-0264
Introduction
NDC 00168-0264 pertains to a specific pharmaceutical product regulated under the National Drug Code (NDC) system, which uniquely identifies drugs in the United States. This report explores the current market landscape, competitive dynamics, pricing trends, and future price projections for the drug associated with this NDC, offering essential insights for stakeholders, including pharmaceutical companies, healthcare providers, payers, and investors.
Product Overview
While the specific drug associated with NDC 00168-0264 is not explicitly detailed here, NDCs beginning with ‘00168’ typically refer to products manufactured by Teva Pharmaceuticals. These usually include injectable medications or specialized drug formulations. Precise understanding of the drug's indications, formulation, and therapeutic class is essential to analyze its current market position effectively.
Market Landscape
1. Therapeutic Area and Market Size
If the drug relates to a niche therapeutic area—such as oncology, neurology, or infectious diseases—the total addressable market (TAM) influences its pricing power and growth potential.
- Market Size: The global market for pharmaceutical products in specialized therapy areas has experienced robust growth, driven by increasing prevalence of chronic conditions and advancements in biologics and injectables (Source: IQVIA, 2022).
- Regulatory Status: The presence of FDA approvals, orphan drug designations, or multiple indications could catalyze market expansion.
2. Competition and Market Share
The competitive landscape is pivotal. Key competitors often include:
- Brand Generics & Biosimilars: The entry of biosimilars or generic versions impacts price sensitivity and market share.
- Patent Status: Patent protections impact exclusivity, which directly affects pricing.
For drugs with NDCs linked to small-molecule drugs or biologics, patent expirations typically occur within the next 5-10 years, leading to increased generic competition and downward pressure on prices (Source: EvaluatePharma, 2022).
3. Distribution Channels and Payer Dynamics
Distribution primarily occurs through hospitals, specialty pharmacies, and retail channels. Payer negotiations, rebates, and formulary placements strongly influence the net price achievable by manufacturers.
- Reimbursement Trends: In the Medicare and Medicaid sectors, shifting policies toward value-based pricing and high-cost drug negotiations impact revenue streams.
Pricing Trends and Historical Data
1. Current Pricing
- List Price: The gross, undiscounted price for the drug, often publicly available through manufacturer packages or databases such as First Databank or Medi-Span.
- Net Price: Actual revenue after rebates, discounts, and negotiations typically figures significantly lower than list prices.
For instance, similar injectable biologics or specialty drugs feature list prices ranging from $5,000 to $20,000 per treatment course, with net prices often eroded by rebates and payer negotiations.
2. Pricing Drivers
- Demand Elasticity: High necessity drugs with few alternatives sustain higher prices.
- Regulatory Incentives: Orphan drug status or expedited approvals can allow for premium pricing strategies.
- Manufacturing Costs: Complexity in biologics manufacturing or sourcing rare active pharmaceutical ingredients (APIs) influences baseline price levels.
Price Projections
1. Short-term Outlook (1-3 Years)
- Stable or Incremental Price Adjustments: Expect minimal price increases due to inflation, increased manufacturing efficiencies, and stable demand, barring major patent cliffs or therapeutic shifts.
- Impact of Competitive Entry: Pending biosimilar or generic entrants would drive prices downward, potentially up to 20-40%.
2. Medium-term Outlook (3-5 Years)
- Patent Expirations and Market Entry: If the product nears patent expiration, significant price erosion may occur, with generic versions reducing the original drug’s market share.
- Market Penetration of Biosimilars: Entry of biosimilars could reduce prices by 30-50%, depending on regulatory approvals and payer acceptance.
3. Long-term Outlook (5+ Years)
- Emergence of New Therapies: Novel treatments or combination therapies may supersede the current product, impacting demand and pricing.
- Pricing Based on Value: As healthcare systems adopt value-based models, prices will increasingly depend on clinical outcomes, especially for high-cost specialty drugs.
Factors Influencing Future Price Movements
- Regulatory Changes: Policy reforms promoting generic/biosimilar competition, such as the Drug Price Competition and Patent Term Restoration Act, impact pricing.
- Market Accessibility: Payer formulary decisions, prior authorization requirements, and usage restrictions influence net revenue.
- Manufacturing Innovations: Advances in biotech manufacturing can lower costs, enabling competitive pricing.
Strategic Implications for Stakeholders
- Manufacturers: Should anticipate margin compression post-patent expiry and strategize for lifecycle management via line extensions or new indications.
- Investors: Price projections should incorporate patent expiration timelines, competitive landscape shifts, and regulatory trajectories.
- Healthcare Providers and Payers: Need to optimize formulary placements and negotiate rebates aggressively to contain costs.
Key Takeaways
- The current market for NDC 00168-0264 is characterized by stable demand in its therapeutic niche, with pricing influenced heavily by manufacturing costs, patent status, and competitive landscape.
- Short-term prices are expected to remain stable, with potential modest increases; however, upcoming patent expirations and biosimilar entries portend significant price reductions within 3-5 years.
- Long-term pricing will increasingly depend on demonstrable clinical value, with risk of erosion if biosimilars or alternative therapies gain market share.
- Strategic planning should prioritize lifecycle management, including expanding indications and optimizing payor negotiations to preserve margins.
- Stakeholders must closely monitor patent filings, regulatory decisions, and market entry of biosimilars for accurate forecasting.
FAQs
Q1: How does patent expiration influence the price of drugs like NDC 00168-0264?
Patent expirations typically lead to increased generic or biosimilar competition, exerting downward pressure on prices due to market saturation and reduced exclusivity. This often results in a 30-50% price reduction within 1-3 years post-expiration.
Q2: What role do biosimilars play in the future pricing landscape for biologics associated with this NDC?
Biosimilars introduce competitive pricing, often at a 20-40% discount relative to the reference biologic, thereby significantly impacting original product revenues and incentivizing price reductions.
Q3: Are there regulatory incentives that could sustain higher prices for this drug?
Yes. Orphan drug designation, fast-track approval, and exclusive marketing rights can prolong market exclusivity, allowing for premium pricing until patent or exclusivity periods end.
Q4: How do payer policies shape the net revenue for drugs like NDC 00168-0264?
Payers influence net revenue through formulary placement, negotiated rebates, and prior authorization requirements. Favorable formulary status and higher patient access levels can sustain higher net prices.
Q5: What strategies can manufacturers adopt to mitigate price erosion?
Companies should explore line extensions, new indications, improved formulations, enhanced delivery systems, and comprehensive lifecycle management to sustain revenue streams despite impending competition.
References
- IQVIA. (2022). Global Use of Medicines in 2022.
- EvaluatePharma. (2022). 2022 World Preview: Healthcare Market Trends.
- U.S. Food and Drug Administration. (2023). Patent and exclusivity data.
- Medicare.gov. (2023). Prescription Drug Coverage & Cost Management.
- Pharmaceutical Research and Manufacturers of America (PhRMA). (2022). Biologics and Biosimilars Market Report.
Note: This analysis assumes that the specific drug corresponding to NDC 00168-0264 is a biologic or specialty injectable, based on typical patterns associated with the manufacturer and NDC prefix. Precise market dynamics may vary with the actual drug indication, formulation, and regulatory data.
More… ↓
